BRSYF (BrainsWay) Moat Score: 6/10 (As of Jul. 08, 2026)


BRSYF BrainsWay Ltd BRSYF
70 GF Score
Price $13.55
GF Value $6.30
! 6 Warning Signs
View Full Analysis

What is BrainsWay Moat Score?

BrainsWay BRSYF 70 Moat Score is 6 as of Jul. 08, 2026. GuruFocus rates BRSYF with a GF Score™ of 70/100 and a GF Value™ of $6.30. The stock has 6 warning signs investors should review. Among 844 Medical Devices & Instruments companies, BrainsWay ranks better than 95.73% on this metric.

BrainsWay has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

BrainsWay has Narrow Moat: BrainsWay Ltd has a strong narrow moat due to its proprietary technology and valuable intellectual property in the medical device sector. The company benefits from some customer loyalty and regulatory barriers, but lacks the scale and distribution network to achieve a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes BrainsWay might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

BrainsWay  (OTCPK:BRSYF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

BrainsWay Moat Score Related Terms

BRSYF vs ABT, SYK, MDT: Moat Score Comparison

For the Medical Devices subindustry, BrainsWay's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BrainsWay Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BrainsWay's Moat Score distribution charts can be found below:

* The bar in red indicates where BrainsWay's Moat Score falls into.


BRSYF
70GF Score
BrainsWay Ltd BRSYF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
BrainsWay (BRSYF) has a Moat Score of 6 as of Jul. 08, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, BrainsWay ranks #36 out of 844 companies in the Medical Devices & Instruments industry, placing it in the top 4.3%.
Is BrainsWay's Moat Score too high?
BrainsWay's current Moat Score is 6. Based on the distribution chart, BrainsWay ranks #36 out of 844 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, BrainsWay has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does BrainsWay's Moat Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, BrainsWay ranks #36 out of 844 companies for Moat Score. This places BrainsWay in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. BrainsWay's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BrainsWay stock overvalued right now?
BrainsWay (BRSYF) has a current Moat Score of 6. The stock's GF Value™ is $6.30, compared to a current price of $13.55 — trading 115.1% above its estimated fair value. The current Moat Score is 6. BrainsWay's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For BrainsWay (BRSYF), the current Moat Score is 6 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BrainsWay (BRSYF) Overvalued in 2026?

Based on GuruFocus' analysis, BrainsWay stock appears to be overvalued. The current stock price of $13.55 is trading 115.1% above its estimated GF Value™ of $6.30.

Key valuation signals for BRSYF:

  • Moat Score: 6
  • GF Value™: $6.30 vs. price of $13.55 (115.1% above fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the BRSYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BrainsWay Business Description

Other Exchanges BWAY:USABWAY:Israel
Address 16 Hartum Street, 14th Floor, RAD Tower, Har HaHotzvim, Jerusalem, ISR, 9777516
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
70GF Score

Get the complete analysis for BRSYF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.55
Price
$6.30
GF Value